Lower neutrophil‐to‐lymphocyte ratio and positive programmed cell death ligand‐1 expression are favorable prognostic markers in patients treated with pembrolizumab for urothelial carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4779
Abstract: Immune checkpoint inhibitors (ICIs) are effective in some cancer patients; however, they may show no efficacy in others. Predictive biomarkers are crucial for appropriately selecting the patients who receive ICI therapy. This study aimed to… read more here.
Keywords: lower neutrophil; lymphocyte ratio; patients treated; urothelial carcinoma ... See more keywords